Valuation: Boundless Bio, Inc.

Market Cap 58.69M 52.41M 48.76M 44.35M 83.73M 5.68B 84.1M 587M 230M 2.9B 220M 216M 9.29B P/E 2026 *
-1x
P/E 2027 * -2.58x
Enterprise Value 58.69M 52.41M 48.76M 44.35M 83.73M 5.68B 84.1M 587M 230M 2.9B 220M 216M 9.29B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87.91%
Yield 2026 *
-
Yield 2027 * -
1 day-1.94%
1 week-3.44%
Current month+0.80%
1 month-11.23%
3 months+0.80%
6 months+121.93%
Current year+110.83%
1 week 2.47
Extreme 2.47
2.71
1 month 2.42
Extreme 2.42
2.93
Current year 0.96
Extreme 0.9612
3.16
1 year 0.96
Extreme 0.9612
3.16
3 years 0.96
Extreme 0.9612
15.24
5 years 0.96
Extreme 0.9612
15.24
10 years 0.96
Extreme 0.9612
15.24
Manager TitleAgeSince
Director of Finance/CFO 64 2021-05-31
President 55 2026-06-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 2018-11-30
Director/Board Member 53 2022-01-04
Director/Board Member 53 2023-10-01
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26
Tang Capital Management LLC
SellCompany -18,300 0.0814%
7/21/26
Tang Capital Management LLC
BuyCompany 2,975 0.0132%
7/16/26
Tang Capital Management LLC
BuyCompany 18,491 0.0823%
Change 5-day change 1-year change 3-year change Capi.($)
-1.94%-3.44%+97.66% - 58.69M
-2.59%-5.70%+40.86%+83.11% 72.13B
+3.23%-10.67%+4.87%+55.97% 49.41B
+1.56%+2.07%+5.03%+33.38% 47.24B
+0.87%-8.17%+298.53%+645.03% 40.32B
+0.39%+0.65%+28.02%+30.24% 42.61B
+1.24%-1.01%+5.56%+105.14% 39.81B
-2.13%-2.18%+7.51%+50.31% 30.52B
+5.32%+0.06%-7.20%-11.30% 23.13B
+3.78%+5.71%+16.43%-1.77% 21.09B
Average +0.97%-3.55%+49.73%+110.01% 36.63B
Weighted average by Cap. +0.78%-4.28%+47.21%+117.56%

Financials

2026 *2027 *
Net sales - -
Net income -57.3M -51.17M -47.61M -43.3M -81.76M -5.55B -82.11M -573M -224M -2.83B -215M -210M -9.07B -71.9M -64.21M -59.74M -54.33M -103M -6.96B -103M -719M -282M -3.55B -270M -264M -11.38B
Net Debt - -
Projected Income Statement - Annual - Boundless Bio, Inc.
Logo Boundless Bio, Inc.
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
Employees
28
Date Price Change Volume
26-10-09 US$2.530 -1.94% 166,791
26-10-08 US$2.580 -2.27% 334,164
26-10-07 US$2.640 +2.72% 116,894
26-10-06 US$2.570 -1.15% 65,184
26-10-05 US$2.600 -0.76% 55,060
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.530USD
Average target price
4.000USD
Spread / Average Target
+58.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Boundless Bio, Inc.
  1. Stock Market
  2. Stocks
  3. BOLD Stock